CofixRX nasal spray was evaluated against two SARS-CoV-2 (Covid) variants of concern: Delta and Omicron. Virus killing tests were performed by the Institute for Antiviral Research at Utah State University with conditions that would mimic a standard dosage of CofixRX applied per manufacturer’s instructions. The procedure and results are detailed in the official report explaining that CofixRX Nasal Spray is >99.5% effective against SARS-CoV-2 variants of concern in this laboratory analysis. These new results add to previous test data that revealed CofixRX is also 100% effective against the viruses Influenza B (“flu”) and RSV (“respiratory syncytial virus”) and 94% effective against HRV-14 (“human rhinovirus B14”). The study proves that the combination of ingredients, including povidone-iodine, in CofixRX is therefore highly virucidal against four distinct viruses tested, including two major variants of concern for SARS-CoV-2: Delta and Omicron.